JP2022549085A - タンパク質／タンパク質融合のリガンド依存性分解を誘導するためのタンパク質タグ - Google Patents

タンパク質／タンパク質融合のリガンド依存性分解を誘導するためのタンパク質タグ Download PDF

Info

Publication number
JP2022549085A
JP2022549085A JP2022516290A JP2022516290A JP2022549085A JP 2022549085 A JP2022549085 A JP 2022549085A JP 2022516290 A JP2022516290 A JP 2022516290A JP 2022516290 A JP2022516290 A JP 2022516290A JP 2022549085 A JP2022549085 A JP 2022549085A
Authority
JP
Japan
Prior art keywords
dcaf15
protein
seq
degron tag
rbm39
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022516290A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549085A5 (enExample
Inventor
エリック エス． フィッシャー，
ショリヤ ソンカー ロイ バーマン，
タイラー ファウスト，
ホジョン ユン，
ラドスロー ピー． ノワク，
Original Assignee
ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド filed Critical ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド
Publication of JP2022549085A publication Critical patent/JP2022549085A/ja
Publication of JP2022549085A5 publication Critical patent/JP2022549085A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022516290A 2019-09-18 2020-09-17 タンパク質／タンパク質融合のリガンド依存性分解を誘導するためのタンパク質タグ Pending JP2022549085A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902275P 2019-09-18 2019-09-18
US62/902,275 2019-09-18
PCT/US2020/051156 WO2021055530A1 (en) 2019-09-18 2020-09-17 Protein tag to induce ligand dependent degradation of protein/protein-fusions

Publications (2)

Publication Number Publication Date
JP2022549085A true JP2022549085A (ja) 2022-11-24
JP2022549085A5 JP2022549085A5 (enExample) 2023-09-26

Family

ID=74883712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022516290A Pending JP2022549085A (ja) 2019-09-18 2020-09-17 タンパク質／タンパク質融合のリガンド依存性分解を誘導するためのタンパク質タグ

Country Status (6)

Country Link
US (1) US12428459B2 (enExample)
EP (1) EP4031163A4 (enExample)
JP (1) JP2022549085A (enExample)
AU (1) AU2020351159A1 (enExample)
CA (1) CA3150308A1 (enExample)
WO (1) WO2021055530A1 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019147783A1 (en) * 2018-01-25 2019-08-01 Dana-Farber Cancer Institute, Inc. Sulfonamide derivatives for protein degradation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2922554T3 (pl) * 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US10550379B2 (en) 2015-06-29 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
CN109715808A (zh) * 2016-04-15 2019-05-03 诺华股份有限公司 用于选择性蛋白质表达的组合物和方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019147783A1 (en) * 2018-01-25 2019-08-01 Dana-Farber Cancer Institute, Inc. Sulfonamide derivatives for protein degradation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TAISUKE UEHARA ET AL.: ""Selective degradation of splicing factor CAPERα by anticancer sulfonamides"", NATURE CHEMICAL BIOLOGY, vol. 13, no. 6, JPN6024035244, 24 April 2017 (2017-04-24), pages 675 - 680, ISSN: 0005695067 *
TING HAN ET AL.: ""Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15"", SCIENCE, vol. Vol. 356, Issue 6336, JPN6024035243, 28 April 2017 (2017-04-28), pages 1 - 13, ISSN: 0005695066 *

Also Published As

Publication number Publication date
EP4031163A1 (en) 2022-07-27
EP4031163A4 (en) 2023-09-13
AU2020351159A1 (en) 2022-02-24
US12428459B2 (en) 2025-09-30
WO2021055530A1 (en) 2021-03-25
US20220402981A1 (en) 2022-12-22
CA3150308A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
Roggenkamp et al. HN1L/JPT2: A signaling protein that connects NAADP generation to Ca2+ microdomain formation
Mohamed et al. The CRL4DCAF1 cullin‐RING ubiquitin ligase is activated following a switch in oligomerization state
AU2019293600A1 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
EP3649149A1 (en) Targeted protein degradation
US20220098251A1 (en) Peptide tags for ligand induced degradation of fusion proteins
WO2004044001A2 (en) Acetylated hmgb1 protein
RS67385B1 (sr) Antitela koja se vezuju za citrulinisani histon 2a i/ili 4
US11655283B2 (en) HLA-G transcripts and isoforms and their uses
IL295623A (en) Molecules targeting mutant ras proteins
JPWO2014126127A1 (ja) ネクロプトーシス関連疾患の治療用医薬組成物及びその有効成分のスクリーニング方法
JP2022549085A (ja) タンパク質／タンパク質融合のリガンド依存性分解を誘導するためのタンパク質タグ
US20160200804A1 (en) Compositions and methods for treating anaplastic thyroid cancer
JP2010254699A (ja) Ｆａｓ関連因子１（ｆａｓａｓｓｏｃｉａｔｅｄｆａｃｔｏｒ１）
JP2025531145A (ja) 老化細胞の除去におけるｎｋｇ２ｄに基づく細胞アダプター分子の使用
EP2780356B1 (fr) Peptides inhibiteurs de l'interaction entre asf1 et les histones, et leurs utilisations
Hołubowicz et al. Scalable purification enables high-quality virus-like particles for therapeutic translation
Semberova et al. CMTM6 suppresses cell-surface expression of death receptor FAS in mice but not in humans
Strauss Identification of Protein Interactors of a Pathological TDP-43 C-Terminal Fragment Using Quantitative Mass Spectrometry
Lai Structural Analysis of Autophagy-related Protein 9 (ATG9)
JP2025537708A (ja) 新規薬剤誘導性分解タグ
Kellner et al. The Nuclear Speckles Protein SRRM2 Is Exposed on the Surface of Cancer Cells. Cells 2024, 13, 1563
WO2025212653A1 (en) Methods including bh3 profiling of car t cells
WO2023023840A1 (en) Novel tumor-specific antigens for cancer stem cells and uses thereof
WO2023107353A2 (en) P53 peptidomimetic macrocycles
HK40112339A (zh) 靶向sars-cov-2抗原的肽和工程化t细胞受体及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230915

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250620